AB Science Secures US Patent for Masitinib in Prostate Cancer Treatment
Event summary
- AB Science received a Notice of Allowance from the USPTO for a patent covering masitinib in treating metastatic castrate-resistant prostate cancer (mCRPC).
- The patent extends IP protection in the US until May 2042, complementing existing European coverage.
- Masitinib is positioned as a combination therapy with docetaxel for mCRPC patients with low metastatic involvement.
- Study AB12003 showed masitinib plus docetaxel significantly improved progression-free survival in mCRPC patients with baseline alkaline phosphatase levels ≤250 IU/L.
The big picture
AB Science's patent win strengthens its IP position in the mCRPC market, a segment with high unmet medical needs and limited therapeutic advancements in the past two decades. The company's focus on masitinib as a combination therapy with docetaxel aligns with the current treatment paradigm for metastatic prostate cancer. With a growing patient population and significant survival challenges, the strategic value of this patent could be substantial.
What we're watching
- Regulatory Milestones
- The pace at which AB Science secures additional international patents for masitinib will determine its global market reach.
- Clinical Validation
- Whether the positive PFS data from study AB12003 will translate into regulatory approvals and commercial success.
- Market Positioning
- How AB Science positions masitinib against existing therapies in the mCRPC space, particularly for patients with low metastatic involvement.
Related topics